A five-arm, phase II basket study has been launched with ~2000 NSCLC patients including PS2 patients, maintenance cohorts, and epidermal growth factor receptor positive (EGFR+)/anaplasplastic lymphoma kinase positive (ALK+) patients treated with erlotinib or crizotinib with and without nivolumab (CHECKMATE 370; NCT02574078). This evidence concerns the gene ALK and non-small cell lung carcinoma.